Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc (NASDAQ: BFRI) is a biopharmaceutical innovator specializing in dermatological treatments through photodynamic therapy and topical antibiotics. This news hub provides investors and healthcare professionals with direct access to the company's official communications and market developments.
Key resources include earnings reports, FDA regulatory updates, clinical trial progress, and partnership announcements. All content is sourced from verified corporate disclosures, ensuring reliable tracking of the company's progress in treating actinic keratoses, impetigo, and related skin conditions.
Users can expect timely updates on product commercialization efforts, financial performance metrics, and therapeutic advancements. The archive serves as both historical reference and current awareness tool for those monitoring Biofrontera's unique position in dermatology innovation.
Bookmark this page for streamlined access to BFRI's latest developments. Combine with SEC filings and medical publications for complete due diligence on the company's dermatology-focused biopharma strategy.
Biofrontera Inc. (NASDAQ:BFRI) announced the completion of the last patient visit in a Phase I study for Ameluz® - PDT aimed at treating mild to severe actinic keratosis (AK). The study, conducted by Biofrontera Bioscience GmbH, explored the safety and tolerability of using three tubes of BF-200 ALA 10% gel in expanded treatment fields. Top line results are anticipated in Q4 2023. CEO Erica Monaco emphasized this milestone as a significant advancement, potentially allowing broader treatment areas and fewer office visits for patients. Actinic keratosis is a common pre-cancerous condition affecting approximately 58 million U.S. residents, highlighting the importance of effective treatment options.
Biofrontera Inc. (NASDAQ:BFRI) announced a significant investment in expanding its salesforce by almost 30%, thereby increasing coverage to 40 territories in 2023. This strategic move aims to enhance outreach for their FDA-approved therapy for actinic keratosis, Ameluz®-PDT, further penetrating dermatology markets. CEO Erica Monaco highlighted the company’s success in 2022, achieving record revenues and market share with a reduced sales team. The addition of 140 years of healthcare experience is expected to bolster growth and market presence. The company remains optimistic about future performance despite potential challenges outlined in their forward-looking statements.
Biofrontera Inc. (NASDAQ:BFRI) is set to showcase its FDA-approved dermatological products at the 2023 American Academy of Dermatology (AAD) Annual Meeting from March 17-21 in New Orleans, LA. The company will demonstrate the photodynamic therapy (PDT) procedure using the RhodoLED lamp at booth #2224. CEO Erica Monaco stated the event is an opportunity to educate dermatologists about the Ameluz PDT therapy for treating actinic keratoses. The AAD Annual Meeting is the largest dermatologic event, attracting about 18,000 attendees, including around 10,000 medical personnel. Biofrontera aims to enhance its outreach among dermatology professionals during this major conference.
FAQ
What is the current stock price of Biofrontera (BFRI)?
What is the market cap of Biofrontera (BFRI)?
